

Hepatology COVID-19 Registry  
Week 15 Report

2 new cases added to the report since week 13

|   | Liver disease, Non-Transplant (N=26)  | Post-liver transplantation (N=24)   |
|---|---|---|
| <b>Gender (%)</b>   | Female = 10 (38.5 %)<br>Male = 16 (61.5 %)  | Female = 11 (45.8 %)<br>Male = 13 (54.2 %)  |
| <b>Median Age (yr) at time of COVID diagnosis (range)</b>                                       | 6.5 (0.16-20)   | 13 (0.5-21)   |
| <b>Etiology of liver disease</b>  | Biliary atresia = 7<br>NAFLD = 5<br>Autoimmune hepatitis = 5<br>Acute Liver Failure = 2<br>Metabolic disorder = 2<br>Others* = 5  | Biliary atresia = 8<br>Acute liver failure = 6<br>Metabolic disorders = 3<br>Tumor = 2<br>Others** = 5  |
| <b>Highest level of care</b>  |   |   |
| Outpatient  | 7   | 17  |
| Hospital floor  | 10  | 3   |
| ICU   | 9   | 4   |
| <b>Immunosuppression at time of COVID diagnosis</b><br>(*some patients were on multiple agents) | No Immunosuppression = 21<br>Azathioprine = 5<br>Steroids = 3   | Tacrolimus = 20<br>Steroids = 10<br>Mycophenolate Mofetil = 9<br>Sirolimus = 3<br>Azathioprine = 1<br>Cyclosporine = 1                                |
| <b>Specific Treatment for COVID</b><br>(*some patients were on multiple agents)                 | IVIg = 4<br>Hydroxychloroquine + Azithromycin = 3<br>Steroids = 3<br>Remdesivir = 2<br>Tocilizumab + Sarilumab = 2<br>Eculizimab = 2<br>Convalescent Plasma = 1<br>Anakinra = 1 | Hydroxychloroquine = 2<br>Convalescent Plasma = 2<br>Azithromycin = 1<br>IVIg = 1<br>Favipiravir = 1<br>Remdesivir = 1<br>Steroid (Dexamethasone) = 1 |
| <b>Highest respiratory support</b>  |   |   |
| None  | 18  | 21  |
| Nasal cannula/CPAP/BiPAP  | 3   | 2   |
| Mechanical ventilation  | 4   | 0   |
| High Frequency Oscillatory ventilation  | 1   | 0   |
| Pending information   | -   | 1   |
| <b>Final clinical outcome</b>   |   |   |
| Death   | 1***  | 0   |
| Recovery  | 22  | 20  |
| Still active in clinical course   | 2   | 3   |
| Pending information   | 1   | 1   |
| <b>Liver related Complications</b>  | Ascites = 7<br>Portal Hypertension Bleeding = 1<br>Infection = 1  | -   |


\*Others CLD: idiopathic cholestasis, GVHD/vanishing bile duct syndrome (Post BMT), IFALD with biliary obstruction, PFIC

\*\* Others PLT: IFALD, Congenital hepatic fibrosis, AIH-Sclerosing cholangitis

\*\*\*Pulmonary hemorrhage, multi-organ failure


Three recipients had multivisceral transplantation; One PLT recipient also had a transplanted kidney.

## Presenting symptoms at time of diagnosis



\*Constitutional symptoms reported: Loss of smell/taste , fever, myalgia, fatigue, sore throat  
# Other symptoms reported: Malaise, anorexia, headache, rash, Kawasaki disease like presentation(MIS-C)

## Change done to Immunosuppressive agent (Post LT)



\*Stopped, decreased the dose, others and No changes  
Commonest agent **stopped**: Mycophenolate Mofetil